Table 1.
N-glycan chains identified in rhuEPO purified from transgenic tobacco lines B1–1 and B2–5
| B1–1 | B2–5 | |||||
|---|---|---|---|---|---|---|
| N-glycans | *S1 | S2 | S3 | S1 | S2 | S3 |
| GlcNAc(Xyl)Man3(Fuc)GlcNAc2 | 27.4 | 27.1 | 5.3 | 79.2 | 53.1 | 30.0 |
| GlcNAc2(Xyl)Man3(Fuc)GlcNAc2 | 0.7 | 19.2 | 30.0 | 48.7 | ||
| GalGlcNAc(Xyl)Man3(Fuc)GlcNAc2 | 72.6 | 35.9 | 21.5 | |||
| Gal2GlcNAc2(Xyl)Man3(Fuc)GlcNAc2 | 5.1 | 13.5 | 6.2 | 4.0 | ||
| GalGlcNAc(Xyl)Man3GlcNAc2 | 8.2 | 3.0 | ||||
| GalGlcNAcMan3(Fuc)GlcNAc2 | 4.3 | |||||
| GalGlcNAc2(Xyl)Man3(Fuc)GlcNAc2 | 2.0 | 10.7 | 9.5 | |||
| †GlcNAc3(Xyl)Man3(Fuc)GlcNAc2 | 1.6 | 5.0 | ||||
| ‡(Fuc)GalGlcNAc(Xyl)Man3(Fuc)GlcNAc2 | 2.4 | |||||
| ¶PentGalGlcNAc(Xyl)Man3(Fuc)GlcNAc2 | 4.7 | 3.8 | ||||
| Pent2GalGlcNAc(Xyl)Man3(Fuc)GlcNAc2 | 7.4 | 7.3 | ||||
| Pent2Gal2GlcNAc2(Xyl)Man3(Fuc)GlcNAc2 | 3.2 | |||||
| Pent3Gal2GlcNAc2(Xyl)Man3(Fuc)GlcNAc2 | 2.2 | |||||
| §HexGalGlcNAc(Xyl)Man3(Fuc)GlcNAc2 | 2.2 | |||||
| HexPentGalGlcNAc(Xyl)Man3(Fuc)GlcNAc2 | 1.4 | |||||
| Hex1Pent2GalGlcNAc(Xyl)Man3(Fuc)GlcNAc2 | 2.9 | |||||
| (Xyl)Man3(Fuc)GlcNAc2 | 2.8 | |||||
| GlcNAc2(Xyl)Man3GlcNAc2 | 1.0 | |||||
| Man5GlcNAc2 | 21.8 | |||||
| Man6GlcNAc2 | 14.1 | |||||
| Man7GlcNAc2 | 1.0 | |||||
| Total (%) | 100 | 100 | 100 | 100 | 100 | 100 |
*
N-glycosylation site
†
N-glycan containing bisected GlcNAc
‡
most probably Lewis A
¶
N-glycan containing additional pentose
§
N-glycan containing additional hexose.